LB Pharmaceuticals Inc Common Stock
LBRXLB Pharmaceuticals is a late-stage biopharmaceutical company focused on developing novel benzamide therapies for neuropsychiatric disorders, including schizophrenia and mood disorders.
Earnings
Next report
Aug 11, 2026 (in a month)Financials
Q1 2026Valuation & ratios
Competitors
By market cap
By revenue growth
By net margin
Profile
LB Pharmaceuticals is a late-stage biopharmaceutical company focused on developing novel benzamide therapies for neuropsychiatric disorders, including schizophrenia and mood disorders. Its core value proposition centers on LB-102, a patented derivative of the antipsychotic amisulpride designed with improved blood-brain barrier permeability to enable once-daily dosing and a superior safety profile. The company aims to address significant unmet needs in the U.S. market by providing treatments that balance rapid efficacy with class-leading tolerability.
LB Pharmaceuticals is a clinical-stage developer seeking to introduce the first benzamide antipsychotic to the U.S. market, leveraging a mechanism of action with extensive established clinical use in Europe.
Questions, answered.
- What is LB Pharmaceuticals Inc Common Stock's market cap?
- LB Pharmaceuticals Inc Common Stock (LBRX) has a market capitalization of $967.6M and trades on NASDAQ.
- Who are LB Pharmaceuticals Inc Common Stock's competitors?
- LB Pharmaceuticals Inc Common Stock's key competitors include Vanda Pharmaceuticals Inc., Alkermes, Inc., Teva Pharmaceutical Industries Limited, and others. These companies compete in similar markets and product categories.
- Who does LB Pharmaceuticals Inc Common Stock partner with?
- LB Pharmaceuticals Inc Common Stock's notable partners include Sanofi S.A., AstraZeneca plc, AbbVie Inc., and others.
- Where is LB Pharmaceuticals Inc Common Stock headquartered?
- LB Pharmaceuticals Inc Common Stock is headquartered in United States of America. It has been publicly traded since 2025.